Image

Study Protocol: 10-Year Follow-Up of Patients Screened for Cardiovascular Risk by the "All With Heart" Association - Development of a Morocco-Specific Risk Score

Study Protocol: 10-Year Follow-Up of Patients Screened for Cardiovascular Risk by the "All With Heart" Association - Development of a Morocco-Specific Risk Score

Recruiting
40 years and older
All
Phase N/A

Powered by AI

Overview

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and their prevalence is steadily increasing in Morocco. Between 2010 and 2012, the "All with heart" Association conducted a large-scale cardiovascular screening campaign in the Greater Casablanca region, involving more than 10,000 adults aged over 40 years. This 10-year follow-up study aims to evaluate long-term cardiovascular outcomes and to develop a Morocco-specific cardiovascular risk score. Follow-up data will be collected through phone calls, WhatsApp, or SMS with participants or their families to document cardiovascular deaths, myocardial infarctions, and strokes. Statistical analyses, including survival analysis and multivariate logistic regression, will be used to identify significant risk factors and to construct a predictive risk model tailored to the Moroccan population. The study received a favorable opinion from the Rabat Ethics Committee. Written informed consent will be obtained from all participants or their families prior to data collection. The findings are expected to enhance understanding of cardiovascular risk evolution in Morocco and to provide a validated, population-specific risk score to support prevention and patient management strategies.

Eligibility

Inclusion Criteria:

  • Adults aged 40 years or older at the time of the initial screening (2010-2012).
  • Individuals who participated in the cardiovascular risk screening campaign conducted by the "All with heart" Association between 2010 and 2012 in the Greater Casablanca region.
  • Moroccan nationality.
  • Participants or family members who provide written informed consent for participation in the 10-year follow-up study.

Exclusion Criteria:

  • Individuals who refuse to participate in the follow-up study.
  • Participants who have moved and cannot be reached by phone, WhatsApp, or SMS.
  • Participants who died from non-cardiovascular causes.
  • Non-Moroccan participants.

Study details
    Cardiovascular Diseases (CVD)

NCT07294937

Moroccan Society of Cardiology

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.